Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance.

The accumulation of hyperphosphorylated tau in neurofibrillary tangles (NFTs) is a neuropathological hallmark of tauopathies, including Alzheimer's disease (AD) and chronic traumatic encephalopathy, but effective therapies directly targeting the tau protein are currently lacking. Herein, we describe a novel mechanism in which the acetylation of tau on KXGS motifs inhibits ...
phosphorylation on this same motif, and also prevents tau aggregation. Using a site-specific antibody to detect acetylation of KXGS motifs, we demonstrate that these sites are hypoacetylated in patients with AD, as well as a mouse model of tauopathy, suggesting that loss of acetylation on KXGS motifs renders tau vulnerable to pathogenic insults. Furthermore, we identify histone deacetylase 6 (HDAC6) as the enzyme responsible for the deacetylation of these residues, and provide proof of concept that acute treatment with a selective and blood-brain barrier-permeable HDAC6 inhibitor enhances acetylation and decreases phosphorylation on tau's KXGS motifs in vivo. As such, we have uncovered a novel therapeutic pathway that can be manipulated to block the formation of pathogenic tau species in disease.
Mesh Terms:
Acetylation, Aged, Aged, 80 and over, Alzheimer Disease, Amino Acid Motifs, Animals, Disease Models, Animal, Female, HEK293 Cells, HeLa Cells, Histone Deacetylase 6, Histone Deacetylase Inhibitors, Histone Deacetylases, Humans, Hydroxamic Acids, Male, Mice, Phosphorylation, Protein Multimerization, Pyrimidines, tau Proteins
Hum. Mol. Genet.
Date: Jan. 01, 2014
Download Curated Data For This Publication
219895
Switch View:
  • Interactions 3